Dr. Omid Hamid, MD

Dr. Hamid practices at Cedars-Sinai Endoscopy in Beverly Hills, California.

Dr. Hamid's NPI, 1215966775, was assigned on June 30, 2006. Dr. Hamid graduated from Keck School of Medicine of USC in 1999. Dr. Hamid holds California license A74223.

Dr. Hamid's primary practice is Cedars-Sinai Endoscopy, at 200 N Robertson Blvd, Beverly Hills, CA 90211 in Los Angeles County. The practice phone is (310) 385-3239.

Dr. Hamid's primary practice is Cedars-Sinai Endoscopy in Beverly Hills, California. Dr. Hamid is also affiliated with Cedars-Sinai Medical Center. The medical group on file is Cedars-Sinai Medical Group. Dmand AI also links Dr. Hamid to 2 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hamid practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Hamid's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Hamid is licensed in California.

Dmand AI lists breast cancer, chronic anemia, chronic leukemia, deep vein thrombosis (DVT), lung cancer, lymphoma and prostate cancer among the conditions Dr. Hamid treats.

CMS data shows 29,688 Medicare services from Dr. Hamid across 45 procedure codes in 2024, for 387 Medicare patients. Medicare paid $2,208,226 for them.

CMS counts 387 Medicare patients who saw Dr. Hamid in 2024. The largest group is 75 to 84, with 163 patients. 75% of them have high cholesterol, and 71% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.35, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hamid's median patient age at 71, with 51% women.

In 2024, Dr. Hamid wrote 230 Medicare Part D claims for 57 patients. 78% of them were for generic drugs. CMS names the drug for 87 of them, across 5 drugs with 11 or more claims each, at $1,381 in total drug cost. In 2023, CMS named 141 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Hamid for performance year 2024, reported as part of a group. Dr. Hamid accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hamid as offering telehealth.

Dmand AI links 200 papers to Dr. Hamid, published from 2009 to 2025. 2019 was the busiest year, with 26. The most frequent topics are Melanoma, Skin Neoplasms and Antibodies, Monoclonal. Dr. Hamid has published most often in Clin Cancer Res. Dr. Hamid's most frequent co-authors are Antoni Ribas, MD, Igor Puzanov, MD and Jedd D. Wolchok, MD.

Dmand AI links Dr. Hamid to 8 clinical trials, 2 of them phase 2 studies. 1 is still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Neoplasm Metastasis. Eli Lilly and Company sponsors the most, 2. Open Payments lists research payments to Dr. Hamid that name 5 trials.

CMS Open Payments shows 815 general payments to Dr. Hamid from 30 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 53% of the total. Bristol-Myers Squibb Company paid the most, $319,201. It also lists 105 research payments totaling $65,099 from 2016 to 2025, naming 5 clinical trials.

Dr. Hamid graduated from Keck School of Medicine of USC in 1999. Dr. Hamid is a member of ASCO.

Dr. Hamid is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.